ILE Isolagen

EXTON, Pa., Sept. 20 /PRNewswire-FirstCall/ -- Isolagen, Inc. (AMEX:ILE) announced today that Nicholas L. Teti, Jr., Chairman and Chief Executive Officer, will deliver a corporate presentation at the UBS Global Life Sciences Conference on Wednesday, September 27 at 8:00 a.m. Eastern Time. A link to the live audio webcast will be available via the "Investors" section of the Company's Web site at http://www.isolagen.com/. A replay of the webcast will also be available approximately 3 hours after the live webcast ends and will be accessible on the Company's Web site. The Global Life Sciences Conference will take place on September 25-28, 2006 at the Grand Hyatt in New York City. ABOUT ISOLAGEN, INC. Isolagen specializes in the development and commercialization of autologous cellular therapies for soft and hard tissue regeneration. The company's product candidates are based on its proprietary Isolagen Process. Autologous cellular therapy is the process whereby a patient's own cells are extracted, allowed to multiply and then injected into the patient. Isolagen's product candidates are designed to be minimally invasive and non-surgical. For additional information, please visit: http://www.isolagen.com/. This press release includes statements that are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained in the release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of Isolagen's control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under the caption "Item 1A. Risk Factors" in Isolagen's most recent Form 10-K filing, as updated in "Item 1A. Risk Factors" in Isolagen's most recent Form 10-Q filing. In addition, Isolagen operates in a highly competitive and rapidly changing environment, and new risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Isolagen disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statement. Readers are also urged to carefully review and consider the various disclosures in Isolagen's annual report on Form 10-K, filed with the SEC on March 14, 2006, as well as other public filings with the SEC since such date. DATASOURCE: Isolagen CONTACT: Investors, Lee M. Stern of The Trout Group, +1-212-477-9007, ; or Media, Mike Beyer of Sam Brown Inc., +1-773-463-4211, , both for Isolagen Web site: http://www.isolagen.com/

Copyright